Revelation Biosciences(REVB) - 2025 Q2 - Quarterly Results

Financial Results Announcement & Corporate Update Revelation Biosciences announced Q2/H1 2025 financial results, highlighting its clinical-stage focus on rebalancing inflammation Q2/H1 2025 Financial Results Announcement Revelation Biosciences, Inc. announced its Q2/H1 2025 financial results, emphasizing its clinical-stage focus on rebalancing inflammation - Revelation Biosciences, Inc. (NASDAQ: REVB) reported financial results for the three and six months ended June 30, 2025, as a clinical-stage life sciences company focused on rebalancing inflammation[1] Corporate Highlights and Cash Position CEO highlighted strategic financial management and Gemini program advancement, with cash and equivalents at $5.2 million as of June 30, 2025 - CEO James Rolke emphasized strategic financial resource maximization and advancing the Gemini program, with Phase 1b data expected this quarter and FDA engagement later this year[2] Cash and Cash Equivalents | Date | Amount (Millions USD) | | :--- | :--- | | June 30, 2025 | $5.2 | | December 31, 2024 | $6.5 | Decrease primarily due to cash used for operating activities. - Current cash and cash equivalents are believed to be sufficient to fund operations through December 2025[2] Summary of Financial Operations Revelation Biosciences reported reduced net loss and lower net cash used for operating activities in Q2/H1 2025 compared to 2024 Key Financial Metrics (Q2 & H1 2025 vs. 2024) The company demonstrated improved financial performance with reduced net loss and decreased cash used in operations for Q2 and H1 2025 Net Cash Used for Operating Activities | Period | 2025 (Millions USD) | 2024 (Millions USD) | Change (YoY) | | :--- | :--- | :--- | :--- | | Three Months Ended June 30 | $4.7 | $5.3 | -$0.6M (Decrease) | Net cash used for operating activities decreased by $0.6 million for the three months ended June 30, 2025, compared to 2024. Net Loss and EPS | Period | Metric | 2025 | 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | :--- | | Three Months Ended June 30 | Net Loss | $(2.4)M | $(8.4)M | $(6.0)M (Reduced Loss) | | | Basic & Diluted Net Loss Per Share | $(7.01) | $(246.27) | $(239.26) (Reduced Loss) | | Six Months Ended June 30 | Net Loss | $(4.5)M | $(11.1)M | $(6.6)M (Reduced Loss) | | | Basic & Diluted Net Loss Per Share | $(13.60) | $(390.02) | $(376.42) (Reduced Loss) | Net loss significantly decreased for both periods in 2025 compared to 2024. Gemini Program: Product & Clinical Development The Gemini program focuses on an intravenously administered PHAD® formulation to reduce inflammation, with positive preclinical and Phase 1 clinical data About Gemini Gemini is an intravenously administered PHAD® formulation designed to reduce inflammation by reprogramming the innate immune system for multiple indications - Gemini is an intravenously administered, proprietary formulation of PHAD® that reduces inflammation damage by reprogramming the innate immune system[4] - Gemini is being developed for multiple indications: prevention/reduction of acute kidney injury (GEMINI-AKI), post-surgical infection (GEMINI-PSI), infection post severe burn (GEMINI-PBI), and treatment of chronic kidney disease (GEMINI-CKD)[5] Clinical Development and Recent Achievements Preclinical and Phase 1 data show Gemini's therapeutic potential, with recent achievements including completing Phase 1b dosing and a $4 million public offering - Multiple preclinical studies have demonstrated Gemini's therapeutic potential in target indications[6] - Positive Phase 1 clinical data for intravenous Gemini treatment met the primary safety endpoint and showed statistically significant pharmacodynamic activity, including upregulation of IL-10[6][7] - Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients[6] - Received gross proceeds of $4 million from public offering in May 2025[6] Consolidated Financial Statements The consolidated statements reflect a significant reduction in net loss for Q2/H1 2025, primarily due to a positive shift in other income/expense Consolidated Statements of Operations The statements show a significant reduction in net loss for Q2/H1 2025, driven by a positive shift in "Other income (expense), net" Key Operating Expenses (Three Months Ended June 30) | Expense Category | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Research and development | $1,317,980 | $1,394,929 | -$76,949 | | General and administrative | $1,143,249 | $1,127,468 | +$15,781 | | Total operating expenses | $2,461,229 | $2,522,397 | -$61,168 | Total operating expenses slightly decreased for the three months ended June 30, 2025. Key Operating Expenses (Six Months Ended June 30) | Expense Category | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Research and development | $2,176,810 | $2,112,511 | +$64,299 | | General and administrative | $2,379,406 | $2,312,024 | +$67,382 | | Total operating expenses | $4,556,216 | $4,424,535 | +$131,681 | Total operating expenses slightly increased for the six months ended June 30, 2025. Net Loss and Other Income (Expense) | Period | Metric | 2025 | 2024 | | :--- | :--- | :--- | :--- | | Three Months Ended June 30 | Net Loss | $(2,444,382) | $(8,389,819) | | | Total other income (expense), net | $16,847 | $(5,867,422) | | Six Months Ended June 30 | Net Loss | $(4,495,467) | $(11,071,252) | | | Total other income (expense), net | $60,749 | $(6,646,717) | The significant reduction in net loss is largely attributable to a positive shift in "Total other income (expense), net" from a large expense in 2024 to a small income in 2025. Consolidated Balance Sheets Total assets decreased to $5.395 million as of June 30, 2025, primarily due to reduced cash, with corresponding decreases in liabilities and equity Key Balance Sheet Items | Item | June 30, 2025 | December 31, 2024 | Change | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $5,173,871 | $6,499,018 | -$1,325,147 | | Total current assets | $5,359,920 | $6,565,717 | -$1,205,797 | | Total assets | $5,395,090 | $6,622,049 | -$1,226,959 | | Total current liabilities | $1,569,306 | $1,913,667 | -$344,361 | | Total stockholders' equity | $3,825,784 | $4,708,382 | -$882,598 | The balance sheet reflects a decrease in total assets, driven by lower cash, and a corresponding decrease in total liabilities and stockholders' equity. - Common Stock shares issued and outstanding increased significantly from 174,104 at December 31, 2024, to 1,534,637 at June 30, 2025, reflecting the public offering in May 2025[6][14] Corporate Information & Disclosures This section provides company information, forward-looking statements, and contact details About Revelation Biosciences, Inc. Revelation Biosciences is a clinical-stage life sciences company leveraging trained immunity with its proprietary Gemini formulation for disease prevention and treatment - Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on trained immunity for disease prevention and treatment using its proprietary Gemini formulation[8] - The company has multiple ongoing programs evaluating Gemini for post-surgical infection prevention, acute kidney injury prevention, and chronic kidney disease treatment[8] Forward-Looking Statements This section cautions investors about inherent risks and uncertainties that could cause actual results to differ materially from projections - The press release contains forward-looking statements, identified by words like "anticipate," "believe," "expect," and "project," which are subject to known and unknown risks and uncertainties[10] - Key risks include the ability to meet financial goals, manage growth, retain employees, successfully develop product candidates, complete clinical studies, obtain regulatory approvals, and the duration of funding[10] Company Contacts Contact information for investor relations and the Chief Financial Officer is provided for inquiries - Investor Relations: Mike Porter (Porter LeVay & Rose Inc., mike@plrinvest.com)[15] - Chief Financial Officer: Chester Zygmont, III (Revelation Biosciences Inc., czygmont@revbiosciences.com)[15]